Evening sweats considerably influence the high quality of life for cancer patients and are typically resistant to remedy. Cannabinoids have been shown to modulate cytokine activity and make hypothermia in animal models, suggesting that they may possibly be a promising candidate for palliation of evening sweats in individuals with oncologic illness.
Assess efficacy of the oral cannabinoid, dronabinol, for palliation of evening sweats in cancer patients.
Design and style:
A retrospective record search identified five cancer patients who had attempted oral dronabinol for palliation of their evening sweats involving 2013 and 2016 and subjectively reported on its efficacy.
A comfort sample of 5 individuals from the outpatient consultative palliative medicine system at Stanford HealthcareCenter was selected from a search of previous records. Sufferers had been integrated if they had a cancer diagnosis and complained of evening sweats that subjectively interfered with their high quality of life. All agreed to attempt oral dronabinol for palliation of their evening sweats.
Sufferers self-reported the impact of oral synthetic dronabinol on their evening sweats.
Therapy of 5 individuals with advanced cancer with synthetic orally administered dronabinol resulted in the profitable management of persistent symptomatic paraneoplastic evening sweats.
Dronabinol and/or medicinal cannabis are promising therapies for palliation of evening sweats in cancer patients.